Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. | Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling ...
Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement. The stock rose 177% to $25.32 and is up about 169% for the past 52 ...
Sensei Biotherapeutics, Inc. SNSE surged on Wednesday following the company’s announcement of its acquisition of Faeth Therapeutics Inc. and a concurrent $200 million private investment. The ...
Investing.com -- Sensei Biotherapeutics (NASDAQ:SNSE) stock soared 200% Wednesday after the company announced its acquisition ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancerPIKTOR is an ...
BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
Sensei Biotherapeutics, Inc. announced key updates regarding its lead program, solnerstotug (SNS-101), a treatment targeting the immune checkpoint VISTA in advanced solid tumors. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results